Revision 1

#8758 Store at -20C

FoxC1 (D8A6) Rabbit mAb

Cell Signaling TECHNOLOGY®

Orders: 877-616-CELL (2355) orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications:	Reactivity:	Sensitivity:	MW (kDa):	Source/Isotype:	UniProt ID:	Entrez-Gene Id:
WB, IP	H M R	Endogenous	75	Rabbit IgG	#Q12948	2296

Product Usage Information

Application	Dilution
Western Blotting	1:1000
Immunoprecipitation	1:200

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

Specificity / Sensitivity

FoxC1 (D8A6) Rabbit mAb recognizes endogenous levels of total FoxC1 protein.

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human FoxC1 protein.

Background

Forkhead box (Fox) proteins are a family of evolutionarily conserved transcription factors defined by the presence of a winged helix DNA binding domain called a Forkhead box (1). In humans, there are over 40 known Fox protein family members, divided into 19 subfamilies, which have evolved to regulate gene transcription in diverse and highly specialized biological contexts throughout development (2). Mutations that disrupt the expression of Fox gene family members have consequently been implicated in a broad array of human disorders, including immunological dysfunction, infertility, speech/language disorders, and cancer (3,4).

FoxC1 (FKHL7, FREAC3) is one of two mammalian FoxC subfamily members. Along with FoxC2, it is expressed in paraxial mesoderm where it functions to promote somitogenesis, myogenesis, and vascular development, possibly under Wnt/β-catenin regulation (5). Mutations in FoxC1 are implicated in anterior segment dysgenesis (ASD) disorders, including congenital glaucoma and Axenfeld-Rieger syndrome (6). Research studies have shown that alterations in FoxC1 expression are linked to breast cancer invasiveness (7,8) and have been shown to modulate proliferation and migration of breast cancer cells *in vitro* (9).

Background References

1. Myatt, S.S. and Lam, E.W. (2007) *Nat Rev Cancer* 7, 847-59.
2. Jackson, B.C. et al. (2010) *Hum Genomics* 4, 345-52.
3. Hannenhalli, S. and Kaestner, K.H. (2009) *Nat Rev Genet* 10, 233-40.
4. Benayoun, B.A. et al. (2011) *Trends Genet* 10, 224-32.
5. Savage, J. et al. (2010) *Differentiation* 79, 31-40.
6. Weisschuh, N. et al. (2008) *Clin Genet* 74, 476-80.
7. Dejeux, E. et al. (2010) *Mol Cancer* 9, 68.
8. Muggerud, A.A. et al. (2010) *Breast Cancer Res* 12, R3.
9. Ray, P.S. et al. (2010) *Cancer Res* 70, 3870-6.

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key

WB: Western Blotting **IP:** Immunoprecipitation

Cross-Reactivity Key

H: human **M:** mouse **R:** rat **Hm:** hamster **Mk:** monkey **Vir:** virus **Mi:** mink **C:** chicken **Dm:** D. melanogaster **X:** Xenopus **Z:** zebrafish **B:** bovine **Dg:** dog **Pg:** pig **Sc:** S. cerevisiae **Ce:** C. elegans **Hr:** horse **GP:** Guinea Pig **Rab:** rabbit **All:** all species expected

Trademarks and Patents

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.